5 Key Takeaways

• 1

  Current diabetic retinopathy therapies are reactive and do not address early neuroinflammatory and metabolic disturbances.

• 2

  Resveratrol is identified as a multi-target modulator that influences mitochondrial health and inflammatory signaling in early diabetic retinopathy.

• 3

  Resveratrol protects mitochondria by activating SIRT1-dependent pathways, improving dynamics and reducing oxidative stress.

• 4

  The compound also suppresses multiple inflammatory mediators and shifts microglial behavior towards a reparative state.

• 5

  While promising, resveratrol is not yet ready for clinical use due to unresolved issues like bioavailability and optimal dosing.